{"id":"NCT00356590","sponsor":"Amgen","briefTitle":"Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012","officialTitle":"Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1998-12","primaryCompletion":"2008-12","completion":"2009-04","firstPosted":"2006-07-26","resultsPosted":"2010-12-08","lastUpdate":"2013-05-14"},"enrollment":468,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Etanercept","otherNames":[]}],"arms":[{"label":"1","type":"OTHER"}],"summary":"This is an open label, multicenter study for extended treatment of patients who have participated in the Immunex clinical study 016.0012. The primary objective of this study is to evaluate the long term safety of etanercept (TNFR:Fc) in patients with early stage rheumatoid arthritis.","primaryOutcome":{"measure":"Total Exposure to Etanercept With Gaps","timeFrame":"Up to 8 years","effectByArm":[{"arm":"Etanercept (Enbrel)","deltaMin":2882.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["15996057","12115173","20957659"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":169,"n":468},"commonTop":["Upper respiratory tract infection","Sinusitis","Injection site erythema","Bronchitis","Headache"]}}